Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real time, alerting patients and caregivers minutes before an episode occurs1
This breakthrough innovation represents a major milestone in Neuraxpharm’s commitment to advancing both digital and personalised solutions that enhance safety and improve quality of life for people living with epilepsy
Interim data from the ongoing SERAS-Home_RWD clinical study currently being prepared for publication
Barcelona, Spain and Düsseldorf, Germany – 27 November, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and mjn-neuro, a start-up that designs, manufactures and markets medical devices, today announce the upcoming launch of EPISERAS®, a pioneering digital health solution designed to predict the risk of epileptic seizures in real time.1
